169 related articles for article (PubMed ID: 20594083)
1. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
2. Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.
de Brito Galvao JF; Kisseberth WC; Murahari S; Sutayatram S; Chew DJ; Inpanbutr N
Am J Vet Res; 2012 Aug; 73(8):1262-72. PubMed ID: 22849687
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma.
McMahon M; Mathie T; Stingle N; Romansik E; Vail D; London C
J Vet Intern Med; 2011; 25(3):511-7. PubMed ID: 21488959
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.
Kozicki AR; Robat C; Chun R; Kurzman ID
Vet Comp Oncol; 2015 Sep; 13(3):229-36. PubMed ID: 23663234
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
[TBL] [Abstract][Full Text] [Related]
7. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
8. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
[TBL] [Abstract][Full Text] [Related]
9. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain.
Fan TM; de Lorimier LP; O'Dell-Anderson K; Lacoste HI; Charney SC
J Vet Intern Med; 2007; 21(3):431-9. PubMed ID: 17552447
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Yang YT; Yuzbasiyan-Gurkan V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012610
[TBL] [Abstract][Full Text] [Related]
11. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs.
Ashton JA; Farese JP; Milner RJ; Lee-Ambrose LM; van Gilder JM
Am J Vet Res; 2005 May; 66(5):885-91. PubMed ID: 15934617
[TBL] [Abstract][Full Text] [Related]
13. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.
Royals SR; Farese JP; Milner RJ; Lee-Ambrose L; van Gilder J
Am J Vet Res; 2005 Nov; 66(11):1961-7. PubMed ID: 16334957
[TBL] [Abstract][Full Text] [Related]
15. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
16. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
Ong SM; Saeki K; Tanaka Y; Nishimura R; Nakagawa T
Vet J; 2016 Dec; 218():51-59. PubMed ID: 27938709
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
18. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
Vail DM; Kurzman ID; Glawe PC; O'Brien MG; Chun R; Garrett LD; Obradovich JE; Fred RM; Khanna C; Colbern GT; Working PK
Cancer Chemother Pharmacol; 2002 Aug; 50(2):131-6. PubMed ID: 12172978
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
Zhang B; Shi ZL; Liu B; Yan XB; Feng J; Tao HM
Anticancer Drugs; 2010 Mar; 21(3):288-96. PubMed ID: 20038829
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines.
Ando T; Ichikawa J; Okamoto A; Tasaka K; Nakao A; Hamada Y
J Orthop Res; 2005 Jul; 23(4):964-9. PubMed ID: 16023013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
